Mutations in the IDH1 and IDH2 genes were shown to cause vulnerability to PARP inhibition in other cancer types; however, talazoparib showed variable sensitivity in a panel of conventionally cultured chondrosarcoma cell lines [27, 36, 39]. This evidence concerns the gene IDH2 and cancer.